How to buy DexCom stock | 397.5

DexCom, Inc is a diagnostics & research business based in the US. DexCom shares (DXCM) are listed on the NASDAQ and all prices are listed in US Dollars. DexCom employs 3,900 staff and has a trailing 12-month revenue of around USD$1.7 billion.

How to buy shares in DexCom

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for DexCom. Find the stock by name or ticker symbol: DXCM. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until DexCom reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$397.5, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of DexCom, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of DexCom. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted DexCom's share price?

Since the stock market crash in March caused by coronavirus, DexCom's share price has had significant positive movement.

Its last market close was USD$397.5, which is 26.73% up on its pre-crash value of USD$291.25 and 118.32% up on the lowest point reached during the March crash when the shares fell as low as USD$182.07.

If you had bought USD$1,000 worth of DexCom shares at the start of February 2020, those shares would have been worth USD$887.47 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,677.45.

DexCom share price

Use our graph to track the performance of DXCM stocks over time.

DexCom shares at a glance

• Key figures

Information last updated 2020-10-20.

Latest market close	USD$397.5
52-week range	USD$145.23 - USD$456.23
50-day moving average	USD$397.744
200-day moving average	USD$390.4424
Wall St. target price	USD$471.17
PE ratio	180.6818
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$2.16

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy DexCom stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of DexCom, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

DexCom price performance over time

Historical closes compared with the close of $397.5 from 2020-10-19

1 week (2020-10-22)	0.43%
1 month (2020-09-29)	-1.16%
3 months (2020-07-29)	-6.93%
6 months (2020-04-29)	15.06%

1 year (2019-10-29)	156.72%
2 years (2018-10-29)	218.92%
3 years (2017-10-27)	792.06%
5 years (2015-10-29)	382.11%

Is DexCom under- or over-valued?

Valuing DexCom stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DexCom's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

DexCom's P/E ratio

DexCom's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 181x. In other words, DexCom shares trade at around 181x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

DexCom's PEG ratio

DexCom's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.0675. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DexCom's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

DexCom's EBITDA

DexCom's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$312.8 million.

The EBITDA is a measure of a DexCom's overall financial performance and is widely used to measure a its profitability.

DexCom financials

Revenue TTM	USD$1.7 billion
Operating margin TTM	16.03%
Gross profit TTM	USD$931.5 million
Return on assets TTM	6.15%
Return on equity TTM	20.05%
Profit margin	11.93%
Book value	$14.192
Market capitalisation	USD$38.1 billion

TTM: trailing 12 months

Shorting DexCom shares

There are currently 4.1 million DexCom shares held short by investors – that's known as DexCom's "short interest". This figure is 8.4% up from 3.8 million last month.

There are a few different ways that this level of interest in shorting DexCom shares can be evaluated.

DexCom's "short interest ratio" (SIR)

DexCom's "short interest ratio" (SIR) is the quantity of DexCom shares currently shorted divided by the average quantity of DexCom shares traded daily (recently around 828624.4). DexCom's SIR currently stands at 5. In other words for every 100,000 DexCom shares traded daily on the market, roughly 5000 shares are currently held short.

However DexCom's short interest can also be evaluated against the total number of DexCom shares, or, against the total number of tradable DexCom shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DexCom's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 DexCom shares in existence, roughly 40 shares are currently held short) or 0.0436% of the tradable shares (for every 100,000 tradable DexCom shares, roughly 44 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against DexCom.

Find out more about how you can short DexCom stock.

DexCom's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like DexCom.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

DexCom's total ESG risk score

Total ESG risk: 29.18

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and DexCom's overall score of 29.18 (as at 10/01/2020) is nothing to write home about – landing it in it in the 50th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like DexCom is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

DexCom's environmental score

Environmental score: 10.43/100

DexCom's environmental score of 10.43 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that DexCom is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

DexCom's social score

Social score: 17.04/100

DexCom's social score of 17.04 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that DexCom is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

DexCom's governance score

Governance score: 13.2/100

DexCom's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that DexCom is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

DexCom's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. DexCom scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that DexCom has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

DexCom, Inc was last rated for ESG on: 2020-10-01.

Total ESG score	29.18
Total ESG percentile	50.12
Environmental score	10.43
Environmental score percentile	6
Social score	17.04
Social score percentile	6
Governance score	13.2
Governance score percentile	6
Level of controversy	2

DexCom share dividends

We're not expecting DexCom to pay a dividend over the next 12 months.

DexCom share price volatility

Over the last 12 months, DexCom's shares have ranged in value from as little as $145.23 up to $456.23. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DexCom's is 0.786. This would suggest that DexCom's shares are less volatile than average (for this exchange).

DexCom overview

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

Frequently asked questions

• What percentage of DexCom is owned by insiders or institutions?

  Currently 0.438% of DexCom shares are held by insiders and 100.533% by institutions.

• How many people work for DexCom?

  Latest data suggests 3,900 work at DexCom.

• When does the fiscal year end for DexCom?

  DexCom's fiscal year ends in December.

• Where is DexCom based?

  DexCom's address is: 6340 Sequence Drive, San Diego, CA, United States, 92121

• What is DexCom's ISIN number?

  DexCom's international securities identification number is: US2521311074

• What is DexCom's CUSIP number?

  DexCom's Committee on Uniform Securities Identification Procedures number is: 252131107